MetaCure Implant For Type 2 Diabetes: Overseas Trials To Wrap Up By 2012
This article was originally published in The Gray Sheet
Executive Summary
MetaCure plans to wrap up three overseas trials by the end of 2012 for its DIAMOND electrostimulator implant for type 2 diabetes in obese patients and will begin a pivotal U.S. trial within the next couple of years to support a PMA submission for type 2 diabetes.
You may also be interested in...
Obesity 2015: Less Invasive Options Will Drive Growth In Market Hungry For Solutions
Nearly half of the world’s adult population will be overweight or obese by 2030 and obesity is tied to more than 40 diseases. Enterprising companies are heeding the call with increasingly less invasive weight loss devices, while an amenable regulatory environment means the marketplace will welcome some of these innovations in 2015.
IntraPace Plans Anti-Obesity Stomach Stimulator Pivotal Trial
IntraPace is in discussions with FDA about an investigational device exemption for its abiliti anti-obesity stomach pacemaker system, and hopes to begin a U.S. pivotal trial by early 2012, according to the company.
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.